Clinical efficacy of a novel autologous blood recovery device during ECMO weaning
10.13303/j.cjbt.issn.1004-549x.2025.11.015
- VernacularTitle:一种用于ECMO撤机时的新型自体血液回收装置的临床应用疗效分析
- Author:
Yufeng LU
1
;
Chuanfa ZHANG
1
;
Dongmei FAN
1
;
Shuo HU
1
;
Xianming WEN
1
;
Ziyou LIU
1
Author Information
1. Department of Cardiac Critical Care, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China
- Publication Type:Journal Article
- Keywords:
extracorporeal membrane oxygenation (ECMO);
blood recovery
- From:
Chinese Journal of Blood Transfusion
2025;38(11):1573-1576
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical efficacy of a novel autologous blood recovery device during the weaning process from extracorporeal membrane oxygenation (ECMO). Methods: A total of 16 patients who received ECMO support and underwent blood recovery during the weaning process from January 2022 to September 2024 at our hospital were included in the experimental group. In contrast, 58 patients who did not receive blood recovery during the weaning process were assigned to the control group. Transfusion components, costs, and changes in routine blood tests and coagulation functions were compared between the two groups from the day of weaning until 48 hours post-weaning. Results: Significant differences were observed in the volumes of red blood cell transfusions, plasma transfusions, and transfusion costs between the two groups from the day of weaning to 48 hours post-weaning (P<0.05). Additionally, in the experimental group, significant differences were noted in hemoglobin (Hb), platelet (Plt), and activated partial thromboplastin time (APTT) results when comparing values before and after extubation (P<0.05). Conclusion: The application of a novel autologous blood recovery device during ECMO weaning reduces patient costs, minimizes wastage of autologous blood, decreases reliance on exogenous blood transfusions, and mitigates the risks associated with allogeneic blood transfusion. This approach merits further promotion for clinical use.
